Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345421 · ClinicalTrials.gov registry record
A Study to Identify and Characterize LAL-D Patients in High-risk Populations
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 640
- Enrollment target
NCT02345421 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 640 participants.
The verdict
NCT02345421 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 640 participants
- Enrollment target
Study Summary
The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345421
The ClinicalTrials.gov registry entry for NCT02345421 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02345421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345421 about?
NCT02345421 is a clinical study titled "A Study to Identify and Characterize LAL-D Patients in High-risk Populations". The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
What is the current status of trial NCT02345421?
This trial is currently terminated. The enrollment target is 640 participants. The study started on 2014-12. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT02345421?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.